Tuberculosis (TB) is a disease caused by a germ that can affect the lungs and in severe cases, the blood and the brain. Almost one million children, mostly from the tropics, suffered from TB in the year 2015. A vaccine called BCG is used to prevent this disease. It is given to babies and is able to prevent severe forms of TB that involve the blood and the brain but does not provide adequate protection from the lung form which is the most common. New vaccines that are able to do a better job at preventing TB in babies are needed. VPM1002 is a vaccine that has been developed to work better than BCG. It has been tested in adults and babies and the results show that it is safe, however we need to know how well it is able to kill TB germs. This study aims to use a tool in the lab to show how well the new vaccine, VPM1002 works in babies from Uganda, an African country where TB is common.
Mr Simon Gwapa Kimuda
Immunomodulation and Vaccines
Medical Research Council/UVRI Uganda Research Unit on AIDS
Prof. Alison Elliott, Medical Research Council/UVRI Uganda Research Unit on AIDS, Uganda
Prof. Gerhard Walzl, Stellenbosch University, South Africa
Dr Helen Fletcher, London School of Hygiene & Tropical Medicine, United Kingdom
Project duration: 12 months